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Abstract
Background: There is accumulating evidence that oxidative stress plays an important role in the pathophysiology
of chronic obstructive pulmonary disease (COPD). One current hypothesis is that the increased oxidant burden in
these patients is not adequately counterbalanced by the lung antioxidant systems.
Objective: To determine the levels of oxidised human serum albumin (HSA) in COPD lung explants and the effect
of oxidation on HSA degradation using an ex vivo lung explant model.
Methods: Parenchymal lung tissue was obtained from 38 patients (15F/23M) undergoing lung resection and
stratified by smoking history and disease using the GOLD guidelines and the lower limit of normal for FEV1/FVC
ratio. Lung tissue was homogenised and analysed by ELISA for total levels of HSA and carbonylated HSA. To
determine oxidised HSA degradation lung tissue explants were incubated with either 200 μg/ml HSA or oxidised
HSA and supernatants collected at 1, 2, 4, 6, and 24 h and analysed for HSA using ELISA and immunoblot.
Results: When stratified by disease, lung tissue from GOLD II (median = 38.2 μg/ml) and GOLD I (median = 48.4
μg/ml) patients had lower levels of HSA compared to patients with normal lung function (median = 71.9 μg/ml, P
< 0.05). In addition the number of carbonyl residues, which is a measure of oxidation was elevated in GOLD I and
II tissue compared to individuals with normal lung function (P < 0.05). When analysing smoking status current
smokers had lower levels of HSA (median = 43.3 μg/ml, P < 0.05) compared to ex smokers (median = 71.9 μg/ml)
and non-smokers (median = 71.2 μg/ml) and significantly greater number of carbonyl residues per HSA molecule
(P < 0.05). When incubated with either HSA or oxidised HSA lung tissue explants rapidly degraded the oxidised
HSA but not unmodified HSA (P < 0.05).
Conclusion: We report on a reliable methodology for measuring levels of oxidised HSA in human lung tissue and
cell culture supernatant. We propose that differences in the levels of oxidised HSA within lung tissue from COPD
patients and current smokers provides further evidence for an oxidant/antioxidant imbalance and has important
biological implications for the disease.
Background
There is accumulating evidence that oxidative stress
plays an important role in the pathophysiology of
chronic obstructive pulmonary disease (COPD) (1). In
particular, studies have demonstrated elevated oxidative
stress is associated with both severity of disease and epi-
sodes of exacerbation (2). The elevated oxidative stress
in these patients is thought to result both directly from
inhaled oxidants in cigarette smoke or pollution and
indirectly due to the release of reactive oxygen species
(ROS) generated by various inflammatory, immune and
epithelial cells (3). One current hypothesis is that the
increased oxidant burden in these patients is not ade-
quately counterbalanced by the lung antioxidant sys-
tems, leading to enhanced pro-inflammatory gene
expression and protein release, inactivation of antipro-
teinases, and as a consequence oxidative tissue injury.
The antioxidants present in serum, airway mucosa,
alveolar lining fluid and cells include mucin, superoxide
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dismutase, glutathione, uric acid, ascorbic acid, and
albumin. Human serum albumin (HSA) is a single non-
glycosylated polypeptide containing 35 cysteine residues
all involved in the formation of stabilising disulphide
bonds except 34cysteine. In plasma, this free thiol group
is quantitatively the most important scavenger of oxi-
dants (4-6), and is thus an important antioxidant within
the body(7).
The formation of carbonyl groups on amino acid resi-
dues as a result of free radical-initiated reactions is well
documented as a marker of protein degradation and
turnover (8, 9). In fact the oxidative modification of pro-
teins and lipids has been implicated in the etiology of a
number of diseases including atherogenesis and diabetes
(10, 11). In particular oxidised HSA is a reliable marker
of oxidative stress in patients with chronic renal failure
and individuals on hemodialysis therapy (12). In light of
these findings the quantification of carbonyl residues
may provide further evidence to support a role of oxida-
tive stress in COPD pathology. There are several meth-
odologies for the quantification of carbonyl residues; in
the majority of them 2,4-dinitrophenyl hydrazine is
allowed to react with the protein carbonyls to form the
corresponding hydrazone, which can be analysed opti-
cally by radioactive counting or immunohistochemistry.
In this study we have adapted a previously published
methodology based on ELISA to analyse the levels of
carbonylated HSA in human lung tissue from COPD
patients (13). In addition, we have investigated the effect
of oxidation on HSA degradation within human lung
tissue explants.
Methods
Patient characteristics for human lung tissue experiments
Parenchymal lung tissue from the normal margin sur-
rounding the tumour site was obtained from 38 patients
(15F/23M) undergoing resection for carcinoma at Guy’s
Hospital London. The study was approved by the St
Thomas’ Hospital Research Ethics committee, reference
number EC01/047, and all volunteers gave their signed
informed consent. The Global Initiative for Chronic
Obstructive Pulmonary Disease (GOLD) guidelines were
used to stratify patients with COPD by disease severity
based on measurements of airflow limitation during
forced expiration (14, 15). Each stage is determined by
the volume of air that can be forcibly exhaled in one
second (FEV1) and by the ratio of FEV1 to the forced
vital capacity (FVC); lower stages indicate less severe
disease. Using the GOLD guidelines our patient cohort
was stratified into the following groups, GOLD I (FEV1/
FVC < 70%, FEV1 ≥ 80% predicted), GOLD II (FEV1/
FVC < 70%, 50% ≤ FEV1 < 80% predicted) and indivi-
duals with normal lung function (FEV1/FVC > 70%,
FEV1 ≥ 90% predicted). Table 1 shows the number of
patients in each GOLD stage and their demographics
which include age, gender, lung function and smoking
history. The patient cohort was also reclassified using
the prediction equations from the National Health and
Nutrition Examination Survey (NHANES) III (16) from
the United States and the Health Survey for England
(HSE) (17) to determine the lower limit of normal
(LLN) for FEV1/FVC. This analysis was performed using
SPSS 14.0 for Windows (SPSS, Chicago, Illinois, USA),
data are given in Table 2. For the purposes of this study
ex-smokers were defined as that had given up smoking
for ≥3 years to ensure for smoking cessation. All
Table 1 Patient characteristics of subjects prior to the
removal of lung tissue
Classification Normal Lung
Function
FEV1/FVC > 70%
FEV1 ≥ 90%
predicted
GOLD I
FEV1/FVC ≤
70%
FEV1 ≥ 80%
Predicted
GOLD II
FEV1/FVC ≤
70%
50% ≤ FEV1 <
80%
Predicted
No. subjects 16 13 9
Age 64.7 ± 14.1 68.2 ± 9.9 64.3 ± 12.3
Gender 6F 7F 2F
10M 6M 7M
Pre-
bronchodilator
FEV1/FVC
0.78 ± 0.08 0.62 ± 0.04 0.53 ± 0.1
Smoking
status
6 current smokers 5 current
smokers
7 current
smokers
8 ex-smokers 5 ex-smokers 2 ex-smokers
2 non-smokers 3 non-smokers
Tissue samples were taken from 38 patients. Patient details including age,
gender, lung function given as the ratio of air that can be forcibly exhaled in
one second (FEV1) to the forced vital capacity (FVC) pre-bronchodilator use
and smoking status. Data given are the mean ± SD of each group.
Table 2 Reclassification of subjects using lower limit of
normal FEV1/FVC to define COPD
Classification Normal Lung
Function
GOLD I GOLD II
No. subjects 12 8 11
Age 63.3 ± 4.7 71.4 ± 2.3 62.5 ± 10.6
Gender 4F 4F 4F
8M 4M 7M
Height (M) 1.71 ± 0.01 1.68 ± 0.03 1.74 ± 0.1
Weight (Kg) 81.0 ± 4.4 67.29 ± 4.3 82.3 ± 9.7
LLN FEV1
predicted
0.91 ± 0.1 0.87 ± 0.02 0.65 ± 0.3
Smoking status 6 current smokers 4 current
smokers
7 current
smokers
5 ex-smokers 3 ex-smokers 2 ex-smokers
2 non-smokers 2 non-smokers
Tissue samples were taken from 31 patients. Patient details including age,
gender, height, weight, lung function given as lower limit of normal (LLN) of
air that can be forcibly exhaled in one second (FEV1) and smoking status.
Data given are the mean ± SD of each group.
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demography data was available up to the date of surgery
and none of the subjects were treated with inhaled or
oral corticosteroids or bronchodilators.
Preparation of human lung tissue for primary cell culture
Lung tissue was finely chopped using dissection scissors
into fragments during several washes with Tyrode’s buf-
fer containing 0.1% sodium bicarbonate. 5-6 explants
(total weight approx. 30 mg) were incubated in a 24 well
plate with RPMI-1650 medium containing 1% penicillin,
1% streptomycin and, 1% gentamycin at 37°C in 5% car-
bon dioxide/air for 16 hours (18). Tissue was then either
incubated with 200 μg/ml HSA or oxidised HSA and
lung tissue and supernatant were harvested at 1, 2, 4, 6,
and 24 hour time points, weighed and stored at -80°C.
Human Serum Albumin ELISA
For measuring total levels of HSA in samples we devel-
oped a specific ELISA assay. Briefly, a 96 well plate was
incubated with 14 ng/ml of rabbit HSA antibody in
coating buffer at 4°C for 6 hours. Following incubation,
the plate was washed and incubated overnight with
PBS-Tween containing 5% milk. The following day the
plate was washed again and a HSA standard curve
(1.5-1000 μg/ml) and samples were added and incubated
at 4C for 2 hours. Following incubation, the plate was
washed and a rabbit anti-HSA antibody conjugated to
HRP was added at a concentration of 130 ng/ml for 2
hours before a final wash. The plate was developed with
the HRP substrate system (TMB), the reaction stopped
with 1 M H2SO4 and optical density read at 450 nm.
The limit of detection for this protocol was 0.3 ng/ml.
Oxidation and derivatisation of the HSA and human
tissue
A stock solution of 30 mg/ml of HSA was oxidised with
equal volumes of 9% hydrogen peroxide and incubated
at room temperature for 30 mins. 100 μl of the oxidised
HSA was then derivatised with 100 μl of 10 mM DNPH
in trifluroacetic acid and 100 μl of H2O. Samples were
then incubated at room temperature for 45 mins, with
vortexing every 10-15 mins. Derivatised protein was
then precipitated on ice with 10% trichloroacetic acid
for 30 mins. Following which the sample was centri-
fuged at 15,000 g for 5 mins and the supernatant
removed. The pellet was then washed 3 times with 100
μl of ethanol/ethyl acetate (1:1) and then allowed to dry.
Finally the pellet was broken up with sonication and re-
suspended in 0.5 mls of 6 M guanidine hydrochloride in
0.5 M potassium phosphate (pH 2.5). The A375 was then
measured and the carbonyl content of the oxidised HSA
standard was then determined using ε375 22,000M
-1 cm-1
(8). For baseline human tissue all samples were deriva-
tised using the method described above.
Carbonylated human serum albumin ELISA
To measure total levels of oxidised human serum albu-
min we adapted a previously published method used to
measure total carbonylated protein (13). Briefly, a 96
well plate was incubated with 10 ng/ml of mouse anti-
HSA antibody in coating buffer at 4°C for 6 hours. Fol-
lowing incubation, the plate was washed and incubated
overnight with 0.1% PBS-Tween containing 5% soya
milk. Following the overnight block, plates were washed
and a derivatised HSA standard curve (0.04 - 45.4 μg/ml)
and derivatised samples added and incubated at 4°C for
2 hours. Following the incubation with samples, the plate
was washed and incubated with 1:5000 rabbit anti-
dinitrophenyl (DNP) antibody, which had a specific anti-
body concentration of 1.0 - 1.7 μg/μl, for 2 hours at 4°C.
Finally after washing, the plate was coated with 60 ng/ml
of anti-rabbit HRP conjugate for 2 hours at 4°C. The
plate was developed with TMB, the reaction stopped
with 1 M H2SO4 and optical density read at 450 nm. The
limit of detection for this was 0.02 ng/ml.
Immunoblot
Samples were separated by electrophoresis on 10% SDS-
polyacrylamide electrophoresis gels. The proteins were
transferred to a nitrocellulose membrane (Bio-Rad) and
blocked overnight with 20% milk. Blots were incubated
with 1:1000 peroxidase conjugated anti-human albumin
antibody (DAKO, Denmark) or 1:1000 anti-DNP anti-
body (Sigma, UK). Sites of antibody binding were visua-
lised by Super signal west (Pierce, UK).
Bicinchonic acid (BCA) assay
Total protein levels of lung homogenates were measured
using a commercially available BCA assay from BioRad
using a Human Serum Albumin (HSA) standard curve.
Limit of detection for HSA was 4 μg/ml.
Lactate dehydrogenase assay
LDH levels were measured in lung supernatant using a
commercially available assay and LDH standard (0.9 -
2000 pg/ml) from Roche (Indianapolis IN, USA). To
standardize for the maximum concentration of LDH
present tissue was homogenised on ice using a sonicator
set at amplitude of 2 microns; for 12 cycles of 10 sec-
onds sonication followed by 20 seconds rest. Following
sonication samples were centrifuged at 15,000 g for 15
minutes at 4°C, and supernatant removed for storage.
The limit of detection of the assay was 0.5 pg/ml.
Statistical analysis
Statistical analyses of results were carried out using Stat-
view software™. The non-parametric Kruskal Wallis test
was used to analyse all of the data except for the paired
data where Non-parametric Wilcoxon Signed Rank
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analysis was carried out. P < 0.05 was considered as
significant.
Multivariate linear regressions for COPD and non-
COPD were performed to test for associations with
HSA and carbonylated HSA. Confounding factors
included for analyses of age, gender, COPD defined as
(FEV1/FVC < 70%; FEV1 ≤ 80% predicted) and smoking
status using Statistica software™. COPD by smoking
interactions were tested in the study by adding a multi-
plicative term to the regression models.
Results
Relationship between baseline levels of human serum
albumin and GOLD I & II
Parenchymal lung tissue from 38 individuals categorised
as GOLD I (mild), II (moderate) or patients with no evi-
dence of airway obstruction, was homogenised and the
levels of HSA analysed using ELISA. As Figure 1 indi-
cates, the level of HSA was decreased in lung tissue
from GOLD II (median = 38.2 μg/ml, IQR = 15.5-48.9,
P < 0.05) and GOLD I patients (median = 48.4 μg/ml,
IQR = 36.6-93.4, P < 0.05) compared to individuals with
normal lung function (median = 71.9 μg/ml, IQR =
52.2-87.6).
Relationship between GOLD I & II and levels of
carbonylated HSA
The tissue homogenates shown in Figure 1 were also
derivatised and the level of carbonyl residues per HSA
molecule measured by ELISA. The numbers of carbonyl
residues together with the values for total HSA shown
in Figure 1 were used to calculate the number of carbo-
nyl residues per HSA molecule. As shown if Figure 2
lung tissue from patients with normal lung function had
very little carbonylated HSA (median = 0.40 carbonyl
residues/HSA molecule, IQR = 0.2-0.7, P < 0.05). How-
ever we found the number of carbonyl residues per
molecule of HSA was elevated in lung tissue from
GOLD I patients (median of 2.3 carbonyl residues/HSA
molecule, IQR = 1.9-2.5, P < 0.05) and was further
elevated to a median of 5.0 carbonyl residues/HSA
molecule in lung tissue from GOLD II patients (IQR =
4.0-7.6, P < 0.05).
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Figure 1 Relationship between GOLD I and II patients and
baseline levels of HSA. Human lung tissue from 38 individuals
classified using the GOLD guidelines was homogenised and
adjusted for total protein. HSA levels were measured in lung
homogenates using ELISA. The median is marked as a solid bar and
expressed as μg/ml. Data was analysed using the non-parametric
Kruskal Wallis test, P < 0.05 was considered to be statistically
significant.
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Figure 2 Relationship between GOLD I and II patients and
baseline levels of carbonylated HSA. Human lung tissue from 38
individuals classified using the GOLD guidelines was homogenised,
derivatised and the number of carbonyl residues measured using
ELISA. The median is marked as a solid bar and expressed as
carbonyl residues/HSA molecule. Data was analysed using the non-
parametric Kruskal Wallis test, P < 0.05 was considered to be
statistically significant.
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Re-classification of subjects using LLN for FEV1/FVC to
define COPD
The GOLD guidelines define airway obstruction as a
fixed FEV1/FVC ratio of 0.70 which has been demon-
strated to misdiagnose airway obstruction because
FEV1/FVC varies with age, height and gender. Thus we
re-classified the subjects in our study using the spirome-
try reference prediction equations from the NHANES
III (16) and NSE (17) studies to confirm that the sub-
jects defined with COPD by the GOLD guidelines did
have a spirometry FEV1/FVC lower that the lower limit
of normal FEV1/FVC (Table 2). From the 38 patients in
this study, data on age, height and weight was only
available for 31 of the subjects. All of the patients classi-
fied with COPD using the GOLD guidelines were also
found to have obstructive lung disease using LLN FEV1/
FVC. Using the LLN re-classified subjects we found
individuals defined by the GOLD guidelines as GOLD II
had significantly decreased levels of HSA compared to
individuals with normal lung function and GOLD I
patients (P = 0.0128, Figure 3A). We also observed that
the number of carbonyl residues/HSA molecule was
increased in individuals defined with COPD using the
LLN for FEV1/FVC and GOLD guidelines stratification
(Figure 3B).
Relationship between baseline levels of human serum
albumin and smoking status
Having observed an inverse relationship between GOLD
I and II patients and levels of HSA we turned our
attention to the other clinical parameters collected in
the study. When analysing smoking histories the data
indicated that current smokers had lower levels of HSA
(median = 43.3 μg/ml, IQR = 23.8-62.0, P < 0.05) com-
pared to ex smokers (median = 71.9 μg/ml, IQR = 38.8-
122.7) and non-smokers (median = 71.2 μg/ml, IQR =
44.9-80.3.7), as shown in Figure 4. We analyzed both
COPD and smoking for an association with the levels of
HSA in the study cohort. The data in Table 3 suggested
an association with COPD and HSA levels (P = 0.001),
and a significant interaction of COPD with smoking
(P < 0.001).
Relationship between smoking status and levels of
carbonylated HSA
Since smoking status influenced baseline levels of HSA
we next investigated whether levels of carbonylated
HSA were also affected. We found no difference
between the number of carbonylated HSA molecules in
ex-smokers (median = 1.9 carbonyl residues/HSA mole-
cule, IQR = 0.3-2.2) and the non-smokers (median =
1.51 carbonyl residues/HSA molecule, IQR = 0.6-2.2,
Figure 5). This was in contrast to lung tissue from cur-
rent smokers which exhibited a significantly greater
number of carbonyl residues per HSA molecule (median
= 3.60 carbonyl residues/HSA molecule, IQR = 0.7-4.9,
P < 0.05).
We analyzed both COPD and smoking for an associa-
tion with the levels of carbonylated HSA in the study
cohort. The data in Table 3 suggested there was an
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Figure 3 Reclassification of subjects using LLN FEV1/FVC to define COPD. Subjects from Figure 1 and 2 were re-classified using the lower
limit of normal (LLN) for FEV1/FVC using prediction equations from the NHANES III and NSE studies to confirm COPD and then categorized by
the GOLD guidelines. Data was analysed using the non-parametric Kruskal Wallis test, P < 0.05 was considered to be statistically significant.
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association with COPD and smoking with carbonylated
HSA levels (P = 0.001), and a significant interaction of
COPD with smoking (P = 0.007).
Degradation of HSA in human lung tissue
As we observed a reduction in the total levels of HSA in
lung tissue from COPD patients and smokers (Figure 1,
3 and 4), but an increase in the number of carbonyl
residues per molecule of HSA (Figure 2, 3 and 4), this
indicated that oxidation may be effecting HSA turn
over. Thus we investigated whether exogenously added
oxidised HSA compared to unmodified HSA, is
degraded in human lung tissue. To evaluate HSA degra-
dation, human lung tissue explants from 12 individuals
(6 ex, 5 current and 1 non-smoker, 5F/7 M, average
FEV1/FVC = 0.64, average age = 68.1) were cultured
with either 200 μg/ml HSA or oxidised HSA for 1, 2, 4,
6 and 24 hours and supernatants analysed using a HSA
ELISA. As shown in Figure 6 when the tissue was incu-
bated with non-oxidized HSA, the levels of HSA in the
supernatant remained relatively constant over the 24
hour duration. In contrast, when tissue was incubated
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Figure 4 Relationship between smoking status and baseline
levels of HSA. Human lung tissue from current smokers (n = 18),
ex smokers (n = 15) and non-smokers (n = 5) was homogenised
and adjusted for total protein. HSA levels were measured in lung
homogenates using ELISA. The median is marked as a solid bar and
expressed as μg/ml. Data was analysed using the non-parametric
Kruskal Wallis test, P < 0.05 was considered to be statistically
significant.
Table 3 Analysis of COPD and smoking interactions on
HSA and carbonylated HSA
HSA
Term Β SE P value
COPD -0.6090 0.0029 0.001
Smoking status -0.0651 0.0580 0.037
COPD × smoking -0.3716 0.0170 <0.001
Carbonylated HSA molecules/HSA molecule
Term Β SE P value
COPD -0.579 0.0053 0.001
Smoking status -0.861 0.0035 0.001
COPD × smoking -0.553 0.0033 0.007
Values are means ± plusorminus SD for non-continuous data unless otherwise
stated
HSA, human serum albumin; COPD, ratio of air forcibly exhaled in one second
(FEV1) to the forced vital capacity (FVC) pre-bronchodilator use (FEV1/FVC <
70%) and FEV1 ≤ 80% predicted; Smoking, current smoking history.
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Figure 5 Relationship between levels of carbonylated HSA and
smoking status. Human lung tissue from current smokers (n = 18),
ex smokers (n = 15) and non-smokers (n = 5) was homogenised.
Samples were derivatised and the number of carbonyl residues
measured using ELISA. The median is marked as a solid bar and
expressed as carbonyl residues/HSA molecule. Data was analysed
using the non-parametric Kruskal Wallis test, P < 0.05 was
considered to be statistically significant.
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with oxidised HSA we observed a dramatic decrease in
the detectable levels of HSA after 4 hours. Indeed, after
24 hours the levels of oxidised HSA had decreased to
105.7 μg/ml compared to 213.5 μg/ml for unmodified
HSA, P < 0.05. The representative blot in Figure 7 for
HSA in lung explant supernatants demonstrates the
same pattern of rapid (A) oxidized HSA turnover over
24 hours compared to (B) unmodified HSA.
Discussion
In the present study, we investigated the oxidation and
degradation of HSA, an abundant sacrificial anti-oxi-
dant, in explants of human lung tissue obtained from
patients with and without COPD. We found parenchy-
mal tissue from COPD patients who were current smo-
kers contained lower levels of total HSA, but had
proportionally greater levels of carbonylated HSA, com-
pared to patients with normal lung function. Lung tissue
from current smokers was also found to contain lower
levels of HSA which was highly carbonylated compared
to lung tissue from ex smokers and non-smokers. Cigar-
ette smoking has been associated for many years with
decreased levels of the anti-oxidants such as ascorbate
and vitamin C (19-21). In addition, recent studies have
shown decreased levels of ascorbic acid and Vitamin E
in COPD patients during exacerbations compared to
stable periods (22). However, this is the first study to
provide evidence of reduced levels of the anti-oxidant
HSA within parenchymal tissue from current smokers
with COPD.
Serum albumin is one of the major antioxidants in the
respiratory tract lining fluid, which also includes mucin,
superoxide dismutase, glutathione, uric acid and ascor-
bic acid. The pathogenesis of COPD is thought to
involve an increased oxidant burden both directly as a
result of smoking and indirectly by the release of ROS
which may not be adequately counterbalanced by the
pulmonary antioxidant systems, resulting in net oxida-
tive stress. Decreased levels of HSA in current smokers
with COPD could therefore contribute to the excessive
accumulation of oxidants which would lead to enhanced
expression of pro-inflammatory mediators, inactivation
of anti-proteinases and ultimately oxidative tissue injury.
It is unlikely that current smokers with COPD are
genetically predisposed to produce lower levels of HSA.
Although single nucleotide polymorphisms in the gene
have been documented, those that affect synthesis of the
protein are extremely rare (23, 24). Alternatively it is
possible that HSA like many genes emerging from the
literature could be epigenetically regulated.
In an attempt to elucidate other possible mechanisms
that could underpin the reduced expression of this anti-
oxidant, we examined whether COPD and smoking
affected the levels of oxidised HSA, and as a result its
degradation. Our data demonstrate that the number of
carbonyl residues per HSA molecule is increased in
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Figure 6 Degradation of HSA and oxidised HSA in human lung
tissue. Human lung tissue (n = 12) was incubated with 200 μg/ml
HSA (open circles) or 200 μg/ml oxidised HSA (filled circles) for 1, 2,
4, 6, and 24 hours. Samples were analysed for the levels of HSA
using ELISA. Values given are the mean ± SEM and are expressed as
μg/ml. The data was statistically analysed using the Wilcoxon-Signed
rank test, * indicates a P value < 0.05.
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Figure 7 Western blot analysis of HSA and oxidised HSA
degradation in human lung tissue. Human lung tissue (n = 12)
was cultured with 200 μg/ml HSA or oxidised HSA and incubated
for 1, 2, 4, 6, or 24 hours. Supernatants were separated on a 12%
SDS-polyacrylamide gel and analysed for HSA expression using
immunoblot. The supernatants cultured with HSA are depicted in
Figure 7a and the supernatants cultured with oxidised HSA are
shown in figure 7b. The blot depicted is a typical example of the
molecular profile of HSA observed for all individuals in the study.
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COPD patients. However within the study we were not
able to obtain lung tissue from GOLD III and IV stage
COPD patients to determine if the expression of HSA
decreases with disease severity. However we could con-
firm that the subjects classified with COPD had obstruc-
tive lung function whether they were defined using the
GOLD guidelines or the lower limit of normal for FEV1/
FVC ratio using the prediction equation from the
NHANES III (16) and NSE(17) studies. With both clas-
sifications we consistently found that GOLD II patients
had decreased levels of HSA molecules which had a
greater number of carbonylated residues. We also
observed that lung explants from current smokers had
elevated numbers of carbonyl residues per HSA mole-
cule compared to those from ex and non-smokers. The
association of COPD and smoking with levels of carbo-
nylated HSA and a COPD × smoking interaction with
levels of HSA indicates that the two cofactors are
required to be present for the effects to manifest. In
support of this, cigarette smoke has been shown to
modify human plasma proteins, producing carbonyl pro-
teins with lost sulfhydryl groups (25, 26). In the clinical
setting it has been shown that the content of oxidised
proteins recovered in BAL is greater in smokers com-
pared with non-smoking control subjects (27). More
importantly Rahman et al reported that plasma anti-oxi-
dant activity is decreased acutely in cigarette smokers,
following acute exacerbations in COPD patients (28). In
addition oxidised HSA has previously been reported in
BAL from COPD patients (29). As the parenchymal
lung explants could not be inflated for histology, it was
not possible to determine the localisation of HSA, which
is a limitation of our study. The carbonylated HSA mea-
sured with the lung tissue could therefore be present in
the intravascular space, extracellular fluid or intracellu-
lar environment. In the clinical setting it would thus be
important to determine if the levels of carbonylated
HSA were derived primarily from the lung or the sys-
temic circulation. Ultimately independent of the source
of HSA, decreased levels of the protein, could contribute
to the oxidative burden within the lungs of smokers
with COPD and potentially result in lung tissue damage.
Of particular note is our observation that lung tissue
from ex smokers, defined as having given up smoking
for at least 3 years, had the same mean concentration of
carbonylated HSA as non-smokers. This may suggest
that smoking cessation could prevent the elevated oxida-
tion and degradation of HSA at least in part, contribut-
ing to the restoration of the oxidant/anti-oxidant
balance within the lung. It is well documented that
smoking cessation in addition to other therapies such as
inhaled steroids and bronchodilators can be effective
treatments for COPD, decreasing the accelerated decline
in lung function and disease progression. If as our data
suggests that the oxidant/anti-oxidant imbalance is
resolved with smoking cessation it further supports the
role of antioxidant disturbances in the progression of
COPD. The data however can not indicate the time
scale required for the resolution of smoking related oxi-
dative stress within the lung.
In this current study we found that the proportion of
carbonylated HSA was greatest in smokers with COPD.
As carbonylated proteins are degraded more rapidly we
hypothesised that in these patients’ total levels of HSA
are decreased due to rapid degradation of the carbony-
lated protein. Using an in vitro lung tissue culture sys-
tem we added exogenous oxidised HSA to model the
effects of oxidised HSA within the extracellular fluid of
the lung. In support of this hypothesis our in vitro data
demonstrated that oxidised HSA was degraded more
rapidly than unmodified HSA in cultured human lung
tissue explants, when analysed by ELISA and western
blot. Larger molecular proteins such as albumin are pri-
marily cleared from the lung by paracellular mechan-
isms, into the systemic circulation. However, as the
supernatant and tissue were analysed in our model it
suggests that carbonylated HSA could be degraded by
the parenchymal lung explants. In support of this find-
ing, it has been demonstrated that both albumin and
other high molecular weight proteins can be directly
cleared by the epithelium through epithelial receptor
mediated endocytosis or pinocytosis, and these proteins
are catabolised through lysosomal degradation (30-32).
Recent evidence suggests that oxidation of HSA
decreases its denaturation enthalpy, suggesting that oxi-
dation of HSA renders it to be denatured more easily
(33). The precise mechanisms involved in the metabolic
turnover of HSA have not been fully elucidated. They
are thought also to involve the uptake of damaged pro-
teins by type A scavenger receptors found on macro-
phages and the sinusoidal liver epithelial cells (34, 35).
The tissue culture experiments were performed on par-
enchymal tissue from donors with and without COPD
and different smoking histories. Although no differences
were observed between the responses of parenchymal
tissue from different donors, the sample size was too
small for statistical analysis, which is a limitation to
determine the effects of smoking and disease on HSA
turnover.
In summary, our study provides further evidence for
the role of oxidative stress in current smokers with
COPD and is the first study to evaluate the effect of oxi-
dation on HSA degradation in human lung tissue. HSA
is currently used clinically to maintain colloid osmotic
pressure and is also viewed as an important antioxidant
in patients with damaged vascular endothelium and
patients with acute lung injury (7, 36, 37). Our data sug-
gests that it might also be important not only to
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consider oxidised HSA as a marker of oxidative stress in
current smokers with COPD, but also the potential ther-
apeutic role of HSA in the homeostasis of the oxidant/
anti-oxidant balance, where there is a large unmet
clinical need.
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